Back to search results

Observational Study of Endocrine Tumors

This study aims to better understand endocrine tumors (growths in glands that make hormones, like the thyroid or adrenal glands). Researchers want to find differences at a molecular level (looking at genes, proteins, and other tiny parts of cells) between tumors that are benign (non-cancerous) and malignant (cancerous). This information could help doctors tell these tumors apart more easily in the future. You may be able to join if you have an endocrine tumor that needs surgery or a biopsy, including those affecting the thyroid, parathyroid, or adrenal glands. The study will look at these molecular profiles over 10 years to see if they can help distinguish between benign and malignant tumors.

Study design
This is an observational study planning to include up to 2415 participants. It is not testing a specific treatment, but rather collecting information.
What's involved
Participants will provide tumor and healthy tissue samples, likely during a scheduled surgery or biopsy.
Compensation
Not stated in the trial record.
Follow-up
The study will track molecular profiles over 10 years to achieve its main goal.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01005654

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Recruiting
Not specifiedAges 4+Observational
National Cancer Institute (NCI)
~2,415 participants
Updated 2026-08-27 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To develop a genetic, epigenetic, metabolomic, and proteomic profile of endocrine neoplasm that will allow us to distinguish benign from malignant tumor for each of the endocrine histologies under study.
Measured over 10 years

Conditions

Endocrine Tumors
Thyroid Neoplasms
Parathyroid Neoplasms
Adrenal Neoplasm
Neuroblastoma

Explore related trials

Adrenal Gland NeoplasmEndocrine NeoplasmNeuroblastomaPancreatic NeoplasmParathyroid Gland NeoplasmThyroid Gland Neoplasm

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Naris Nilubol, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

Kristine J Villaruel
[email protected]
(240) 858-7033
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants who have an endocrine neoplasm based on radiographic and biochemical testing, or histologically/cytologically proven lesions of the thyroid, parathyroid, adrenal, extra-adrenal endocrine nests, paragangliomas, neuroblastomas, gastrointestinal
Participants referred to the Endocrine Consult Service on other protocols for surgical evaluation of endocrine disorders based on radiographic and biochemical testing, or histologically/cytologically proven lesions of the thyroid, parathyroid, adrenal, extra-adrenal endocrine nests, paragangliomas, neuroblastomas and pancreas.
Participants must have an ECOG performance score of 0-2.
Participants must have physical examination parameters within acceptable limits by standard of practice guidelines prior to biopsy or surgery.
Participants must be planning to undergo surgery or biopsy as part of their treatment plan. Note: Participants will not be enrolled exclusively for the procurement of tissue samples.
Age \>= 4 years of age.

What this trial measures

  • To develop a genetic, epigenetic, metabolomic, and proteomic profile of endocrine neoplasm that will allow us to distinguish benign from malignant tumor for each of the endocrine histologies under study.10 years

    To develop a genetic, epigenetic, metabolomic, and proteomic profile of endocrine neoplasm that will allow us to distinguish benign from malignant tumor for each of the endocrine histologies under study.